# | Title | Journal | Year | Citations |
---|
1 | A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? | Journal of Virus Eradication | 2020 | 183 |
2 | The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries | Journal of Virus Eradication | 2017 | 123 |
3 | Are new antiretroviral treatments increasing the risks of clinical obesity? | Journal of Virus Eradication | 2019 | 79 |
4 | Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection | Journal of Virus Eradication | 2016 | 73 |
5 | HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide? | Journal of Virus Eradication | 2015 | 71 |
6 | CNS reservoirs for HIV: implications for eradication | Journal of Virus Eradication | 2015 | 69 |
7 | Establishment of latent HIV-1 reservoirs: what do we really know? | Journal of Virus Eradication | 2019 | 69 |
8 | Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India) | Journal of Virus Eradication | 2021 | 67 |
9 | HIV pre-exposure prophylaxis for women | Journal of Virus Eradication | 2016 | 63 |
10 | Impact of COVID-19 on people living with HIV: A review | Journal of Virus Eradication | 2020 | 63 |
11 | Minimum costs to manufacture new treatments for COVID-19 | Journal of Virus Eradication | 2020 | 63 |
12 | The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries | Journal of Virus Eradication | 2017 | 63 |
13 | Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C | Journal of Virus Eradication | 2016 | 60 |
14 | Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam | Journal of Virus Eradication | 2016 | 57 |
15 | Willingness to participate and take risks in HIV cure research: survey results from 400 people living with HIV in the US | Journal of Virus Eradication | 2017 | 57 |
16 | Cytomegalovirus vaccines under clinical development | Journal of Virus Eradication | 2016 | 54 |
17 | CNS reservoirs for HIV: implications for eradication | Journal of Virus Eradication | 2015 | 54 |
18 | HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide? | Journal of Virus Eradication | 2015 | 51 |
19 | Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification | Journal of Virus Eradication | 2015 | 50 |
20 | The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals | Journal of Virus Eradication | 2019 | 49 |
21 | Innovative strategies using communications technologies to engage gay men and other men who have sex with men into early HIV testing and treatment in Thailand | Journal of Virus Eradication | 2015 | 48 |
22 | Achieving UNAIDS 90-90-90 targets for pregnant and postpartum women in sub-Saharan Africa: progress, gaps and research needs | Journal of Virus Eradication | 2018 | 47 |
23 | Willingness to participate and take risks in HIV cure research: survey results from 400 people living with HIV in the US | Journal of Virus Eradication | 2017 | 46 |
24 | Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection | Journal of Virus Eradication | 2016 | 45 |
25 | Traversing the cascade: urgent research priorities for implementing the ‘treat all’ strategy for children and adolescents living with HIV in sub-Saharan Africa | Journal of Virus Eradication | 2018 | 44 |
26 | Cytomegalovirus vaccines under clinical development | Journal of Virus Eradication | 2016 | 44 |
27 | Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? | Journal of Virus Eradication | 2018 | 44 |
28 | Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations | Journal of Virus Eradication | 2017 | 42 |
29 | HIV/AIDS in the South-East Asia region: progress and challenges | Journal of Virus Eradication | 2016 | 40 |
30 | Recruitment and ethical considerations in HIV cure trials requiring treatment interruption | Journal of Virus Eradication | 2015 | 39 |
31 | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018 | Journal of Virus Eradication | 2018 | 39 |
32 | Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C | Journal of Virus Eradication | 2016 | 39 |
33 | Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations | Journal of Virus Eradication | 2017 | 39 |
34 | Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19 | Journal of Virus Eradication | 2020 | 38 |
35 | Establishment of latent HIV-1 reservoirs: what do we really know? | Journal of Virus Eradication | 2019 | 38 |
36 | Human cytomegalovirus (CMV) in Africa: a neglected but important pathogen | Journal of Virus Eradication | 2016 | 37 |
37 | Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification | Journal of Virus Eradication | 2015 | 36 |
38 | Are new antiretroviral treatments increasing the risks of clinical obesity? | Journal of Virus Eradication | 2019 | 35 |
39 | What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent | Journal of Virus Eradication | 2015 | 34 |
40 | The impact of Thailand's public health response to the HIV epidemic 1984–2015: understanding the ingredients of success | Journal of Virus Eradication | 2016 | 34 |
41 | Recruitment and ethical considerations in HIV cure trials requiring treatment interruption | Journal of Virus Eradication | 2015 | 34 |
42 | Innovative strategies using communications technologies to engage gay men and other men who have sex with men into early HIV testing and treatment in Thailand | Journal of Virus Eradication | 2015 | 34 |
43 | How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP | Journal of Virus Eradication | 2018 | 34 |
44 | The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals | Journal of Virus Eradication | 2019 | 34 |
45 | HIV pre-exposure prophylaxis for women | Journal of Virus Eradication | 2016 | 33 |
46 | HIV/AIDS in the South-East Asia region: progress and challenges | Journal of Virus Eradication | 2016 | 33 |
47 | India's HIV programme: successes and challenges | Journal of Virus Eradication | 2016 | 31 |
48 | High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C | Journal of Virus Eradication | 2017 | 31 |
49 | What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent | Journal of Virus Eradication | 2015 | 31 |
50 | Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam | Journal of Virus Eradication | 2016 | 30 |